Carl W. Langberg
Papers
1
Total Citations
19
H-Index
1
About
Carl W. Langberg is a leading oncological surgeon whose research centers on testicular cancer, specifically pioneering surgical alternatives to cytotoxic therapies. His major contribution lies in demonstrating the viability of primary retroperitoneal lymph node dissection (RPLND) as a treatment for low-volume metastatic seminoma, aiming to reduce long-term morbidity from standard chemotherapy. This work, highlighted in his 2024 study from the Swedish Norwegian Testicular Cancer Group—which has already garnered 19 citations—provides crucial population-based evidence for a paradigm shift in managing this disease. By assessing oncological efficacy and surgical safety, Langberg’s research directly addresses an unmet clinical need, offering patients a less toxic path to cure. His findings are reshaping treatment protocols and inspiring further investigation into surgery-first approaches for seminoma, marking him as a key figure in urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1